ESTRELLA IMMUNOPHARMA, INC. Payments for Brokerage Fees
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Payments for Brokerage Fees of $500 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForBrokerageFees · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. payments for brokerage fees for the quarter ending 2026-06-30 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. payments for brokerage fees for the quarter ending 2026-03-31 was $500.00, a 28.57% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. payments for brokerage fees for the quarter ending 2025-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. payments for brokerage fees for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. payments for brokerage fees for fiscal 2023 was $0.00.
| Period end | Payments for Brokerage Fees | Payments for Brokerage Fees 3 month | Payments for Brokerage Fees 6 month | Payments for Brokerage Fees 9 month | Payments for Brokerage Fees 12 month | Payments for Brokerage Fees 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $500.00 10-Q · filed 2026-08-13 | $500.00 derived: sum of 3 quarters · filed 2026-08-13 | $500.00 derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $500.00 10-Q · filed 2026-05-18 | $500.00 derived: sum of 2 quarters · filed 2026-08-13 | $500.00 derived: sum of 3 quarters · filed 2026-08-13 | $300.00 derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | -$200.00 derived: sum of 3 quarters · filed 2026-08-13 | $500.00 10-Q · filed 2026-08-13 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$200.00 derived: sum of 2 quarters · filed 2025-11-12 | $500.00 10-Q · filed 2025-11-12 | -$63.50K derived: sum of 4 quarters · filed 2026-03-18 | ||
| 2025-06-30 | -$200.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $500.00 10-Q · filed 2025-08-12 | -$63.50K derived: sum of 3 quarters · filed 2026-03-18 | $30.50K derived: sum of 4 quarters · filed 2026-03-18 | ||
| 2025-03-31 | $700.00 10-Q · filed 2025-05-14 | -$63.30K derived: sum of 2 quarters · filed 2026-03-18 | $30.70K derived: sum of 3 quarters · filed 2026-03-18 | |||
| 2024-12-31 | $30.00K 10-KT · filed 2025-03-25 | -$64.00K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $30.00K 10-K · filed 2026-03-18 | $30.00K 10-Q · filed 2025-11-12 | ||
| 2024-09-30 | $94.00K 10-Q · filed 2024-11-14 | |||||
| 2024-06-30 | $146.00K 10-KT · filed 2025-03-25 | $146.00K 10-Q · filed 2024-11-14 | $145.62K 10-K · filed 2024-09-27 | |||
| 2023-06-30 | $0.00 10-K · filed 2024-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |